Fatemeh Amirian, Mohammad Ali Yaghoubi, Hassan Mehrad-Majd, Masoud Mohebbi, Parvin Layegh, Leila Vazifeh-Mostaan, Maliheh Dadgar Moghaddam, Zahra Amirian, Ghazaleh Taghavi
Faculty of Medicine, Department of Internal Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Cancer Rep (Hoboken). 2025 May;8(5):e70191. doi: 10.1002/cnr2.70191.
Thyroid Autoantibodies (TgAbs) are associated with autoimmune thyroid disorders and are also used in thyroid cancer follow-up to monitor for recurrence of disease. This study aimed to explore the potential utility of TgAbs as a surrogate tumor marker and examine the relationship between fluctuations in TgAbs levels and disease recurrence in patients with Differentiated Thyroid Cancer (DTC).
This cohort study was conducted on a sample of 97 patients who underwent thyroidectomy for differentiated thyroid cancer (DTC) between the years 2017 and 2021. Following surgery (with or without lymph node dissection), levothyroxine therapy and 131 iodine were prescribed (as necessary). Regular laboratory evaluations were conducted, which involved measuring Tg and TgAb at 3 and 6 months postoperatively. Patients were classified based on recurrence rate and different levels of TgAb, and ROC analysis was applied. All data were analyzed with SPSS24, and a p-value < 0.05 was considered statistically significant.
For low-risk patients, TgAb trends over time showed an increase at 6 months, while for high-risk patients, TgAb levels continuously rose starting from 3 months. Although TgAb levels above the functional sensitivity threshold did not predict recurrence overall, changes in TgAb levels at 6 months compared to 3 months after surgery were indicative of recurrence.
In the entire population, having TgAb levels higher than the functional sensitivity threshold had no risk of various relapses. However, changes in TgAb serum levels at 6 months after surgery, compared to 3 months after surgery, can serve as an indication of tumor recurrence.
甲状腺自身抗体（TgAbs）与自身免疫性甲状腺疾病相关，也用于甲状腺癌随访以监测疾病复发。本研究旨在探讨TgAbs作为替代肿瘤标志物的潜在效用，并研究分化型甲状腺癌（DTC）患者中TgAbs水平波动与疾病复发之间的关系。
本队列研究对2017年至2021年间因分化型甲状腺癌（DTC）接受甲状腺切除术的97例患者进行了抽样。手术后（有或无淋巴结清扫），根据需要给予左甲状腺素治疗和131碘。进行定期实验室评估，包括在术后3个月和6个月测量Tg和TgAb。根据复发率和不同水平的TgAb对患者进行分类，并应用ROC分析。所有数据用SPSS24进行分析，p值<0.05被认为具有统计学意义。
对于低风险患者，TgAb水平随时间变化在6个月时升高，而对于高风险患者，TgAb水平从3个月开始持续上升。虽然高于功能敏感性阈值的TgAb水平总体上不能预测复发，但术后6个月与3个月相比TgAb水平的变化提示复发。
在整个人群中，TgAb水平高于功能敏感性阈值并无各种复发风险。然而，术后6个月与术后3个月相比TgAb血清水平的变化可作为肿瘤复发的指标。
